Related Experiment Video
Updated: May 20, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Discovery of ITX 4520: a highly potent orally bioavailable hepatitis C virus entry inhibitor
Gopi Kumar Mittapalli1, Fang Zhao, Andrew Jackson
1iTherX Pharmaceuticals, Inc., San Diego, CA 92191-0530, USA.
Abstract:
The manuscript reports an identification of a highly potent, orally bioavailable hepatitis C virus entry inhibitor through optimization of a previously reported class of molecules (1) that were not stable in the rat plasma. Compound 39 (ITX 4520) exhibited an excellent PK profile in both rats and dogs with good oral exposure, half-life and oral bioavailability. The compound is also well-tolerated in the preliminary in vivo toxicity studies and has been selected as a pre-clinical candidate for our HCV clinical pipeline.
Related Concept Videos
Viral Hepatitis I: Introduction
Hepatitis
Inhibitors of Viral Protein Synthesis
Dipeptidyl Peptidase 4 Inhibitors
Drug Discovery: Overview

